NCT04052880 : Phase 2 - SubQ Dara + Dose-Atten. Bortezomib, Lenalidomide, Dex New MM >70 years
Updated: May 24, 2022
Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical response.
Sponsor
Ajai Chari
Collaborator
Janssen, LP
ClinicalTrials.gov Identifier: NCT04052880
Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients
First Posted: August 12, 2019
Click here for details on ClinicalTrials.gov
* Bortezomib (Velcade)
* Lenalidomide (Revlimid)
* Dexamethasone (Decadron)
* Daratumumab (Darzalex)
Location
United States, New York
New York: Tisch Cancer Institute Mount Sinai Hospital New York